Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial by Menon, Usha et al.
Articles
2182 www.thelancet.com   Vol 397   June 5, 2021
Ovarian cancer population screening and mortality after 
long-term follow-up in the UK Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS): a randomised controlled trial
Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Naveena Singh, Andy Ryan, Chloe Karpinskyj, Giulia Carlino, Julie Taylor, 
Susan K Massingham, Maria Raikou, Jatinderpal K Kalsi, Robert Woolas, Ranjit Manchanda, Rupali Arora, Laura Casey, Anne Dawnay, Stephen Dobbs, 
Simon Leeson, Tim Mould, Mourad W Seif, Aarti Sharma, Karin Williamson, Yiling Liu, Lesley Fallowfield, Alistair J McGuire, Stuart Campbell, 
Steven J Skates, Ian J Jacobs, Mahesh Parmar
Summary
Background Ovarian cancer continues to have a poor prognosis with the majority of women diagnosed with advanced 
disease. Therefore, we undertook the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) to determine 
if population screening can reduce deaths due to the disease. We report on ovarian cancer mortality after long-term 
follow-up in UKCTOCS.
Methods In this randomised controlled trial, postmenopausal women aged 50–74 years were recruited from 13 centres 
in National Health Service trusts in England, Wales, and Northern Ireland. Exclusion criteria were bilateral 
oophorectomy, previous ovarian or active non-ovarian malignancy, or increased familial ovarian cancer risk. The trial 
management system confirmed eligibility and randomly allocated participants in blocks of 32 using computer 
generated random numbers to annual multimodal screening (MMS), annual transvaginal ultrasound screening 
(USS), or no screening, in a 1:1:2 ratio. Follow-up was through national registries. The primary outcome was death 
due to ovarian or tubal cancer (WHO 2014 criteria) by June 30, 2020. Analyses were by intention to screen, comparing 
MMS and USS separately with no screening using the versatile test. Investigators and participants were aware of 
screening type, whereas the outcomes review committee were masked to randomisation group. This study is 
registered with ISRCTN, 22488978, and ClinicalTrials.gov, NCT00058032.
Findings Between April 17, 2001, and Sept 29, 2005, of 1 243 282 women invited, 202 638 were recruited and randomly 
assigned, and 202 562 were included in the analysis: 50 625 (25·0%) in the MMS group, 50 623 (25·0%) in the USS group, 
and 101 314 (50·0%) in the no screening group. At a median follow-up of 16·3 years (IQR 15·1–17·3), 2055 women were 
diagnosed with tubal or ovarian cancer: 522 (1·0%) of 50 625 in the MMS group, 517 (1·0%) of 50 623 in the USS group, 
and 1016 (1·0%) of 101 314 in the no screening group. Compared with no screening, there was a 47·2% (95% CI 
19·7 to 81·1) increase in stage I and 24·5% (–41·8 to –2·0) decrease in stage IV disease incidence in the MMS group. 
Overall the incidence of stage I or II disease was 39·2% (95% CI 16·1 to 66·9) higher in the MMS group than in the no 
screening group, whereas the incidence of stage III or IV disease was 10·2% (–21·3 to 2·4) lower. 1206 women died of 
the disease: 296 (0·6%) of 50 625 in the MMS group, 291 (0·6%) of 50 623 in the USS group, and 619 (0·6%) of 101 314 in 
the no screening group. No significant reduction in ovarian and tubal cancer deaths was observed in the MMS (p=0·58) 
or USS (p=0·36) groups compared with the no screening group.
Interpretation The reduction in stage III or IV disease incidence in the MMS group was not sufficient to translate into 
lives saved, illustrating the importance of specifying cancer mortality as the primary outcome in screening trials. 
Given that screening did not significantly reduce ovarian and tubal cancer deaths, general population screening 
cannot be recommended.
Funding National Institute for Health Research, Cancer Research UK, and The Eve Appeal.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Ovarian cancer remains the most deadly of all 
gynaecological cancers. Most patients (58%) are 
diagnosed at an advanced stage (III or IV), which is 
associated with poor survival (5-year survival is 27% for 
stage III and 13% for stage IV ovarian cancer).1 The 
greater than 90% survival rates in women detected 
at stage I1 has spurred international efforts in early 
detection, spanning across four decades.2–6 All trials have 
used combinations of the biomarker CA125 and pelvic 
imaging using transvaginal ultrasound scans (TVS). 
Despite these extensive endeavours, to date there is no 
evidence that screening for ovarian cancer saves lives.7–9
In our multicentre randomised trial (UK Collabora-
tive Trial of Ovarian Cancer Screening [UKCTOCS]), 
202 638 women from the general population were 
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randomly assigned to two annual screening groups—
multimodal screening (MMS; longitudinal CA125 and 
second line TVS) and ultrasound screening (USS; TVS 
first and second-line test), and a no screening group. We 
reported previously (median follow-up of 11·1 years), that 
an absolute proportion of 13% more women with ovarian, 
tubal, and peritoneal cancer were diagnosed with stage I 
or II disease in the MMS group than in the no screening 
group. There was no change in stage in the USS group. 
There was no evidence of a reduction in disease-specific 
deaths in either screened group compared with the no 
screening group using the Cox version of the log-rank 
test. The observed reduction in deaths was delayed and 
the cumulative mortality curves appeared to be diverging 
at the time of previous reporting.9 Therefore, we aimed 
to continue follow-up and report here on the long-
term mortality effects of ovarian cancer screening in 
UKCTOCS.
Methods
Study design and participants
We did a randomised controlled trial (UKCTOCS) of 
postmenopausal women aged 50–74 years from the 
general population recruited through 13 centres in 
National Health Service (NHS) Trusts in England, Wales, 
and Northern Ireland with use of age-sex registers of 
27 primary care trusts.10
We commissioned specialised software from the NHS 
to randomly select women aged 50–74 years and then 
flag them on primary care trusts’ registers and allow 
electronic transfer of their personal and general practice 
details. We then sent women personal invitations and 
logged replies on the trial management system. Women 
attended a recruitment clinic at the regional centre 
where they viewed an information video, completed a 
recruitment questionnaire, and provided written consent 
and a baseline serum sample. We scanned recruitment 
questionnaires at the coordinating centre into a bespoke 
trial management system.
Inclusion criteria were 50–74 years of age and 
postmenopausal status. Exclusion criteria were bilateral 
oophorectomy, previous ovarian or active non-ovarian 
malignancy, or increased familial ovarian cancer risk.
Ethical approval was provided by the UK North West 
Multicentre Research Ethics Committees (00/8/34) on 
June 23, 2000. All participants provided written informed 
consent. The trial design has been previously published 
and the protocol is available online.9–12
Randomisation and masking
The trial management system confirmed eligibility and 
then randomly allocated women using the Visual Basic 
randomisation statement and the RND function to 
annual screening using the MMS or USS strategy, or no 
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Research in context
Evidence before this study
We searched PubMed from Jan 1, 2015, to Dec 31, 2020, with 
no language restrictions for randomised controlled trials for 
ovarian cancer screening that reported mortality data. 
The following keywords were used to search the database: 
“ovarian cancer” AND “randomised controlled trial” AND 
“screening” AND “mortality”. We found two relevant 
publications. In the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS; n=202 638), at a median follow-up of 
11·1 years, no significant reduction in deaths from ovarian 
cancer was seen in either of the screen groups (multimodal or 
ultrasound) compared with the no screening group. 
A reduction in deaths was seen but was delayed and only 
apparent after about 7 years. There was a suggestion that 
15% fewer women in the multimodal screening group and 
11% fewer in the ultrasound screening group died from ovarian 
cancer compared with the no screening group. Additionally, 
a significantly greater proportion (13%) of women with ovarian 
cancers in the multimodal group but not in the ultrasound 
group were found at an earlier stage (stage I and II) compared 
with the no screening group. As the data did not definitively 
answer the question of whether screening saved lives, 
follow-up was continued to gather more evidence. The Ovarian 
Cancer Screening arm of the Prostate Lung Colorectal Ovarian 
(PLCO) cancer trial in the USA is the only other large 
randomised controlled trial (n=78 216) to explore mortality 
benefit. Following extended follow-up (median 14·7 years), 
the trial confirmed previous findings of no ovarian cancer 
mortality reduction between the screen and control arms.
Added value of this study
Long-term follow-up (median follow-up >16 years after 
recruitment) in the largest ovarian cancer screening trial, 
to our knowledge, provides definitive new evidence that 
neither screening approaches used in UKCTOCS reduced 
deaths from ovarian cancer, compared with no screening. 
This result was despite a 47·2% increase in incidence of 
women with ovarian and tubal cancer diagnosed at stage I 
and 24·5% decrease in those diagnosed with stage IV disease 
in the multimodal group compared with the no screening 
group. Importantly, however, there was only a 10·2% decrease 
in overall incidence of stage III or IV disease.
Implications of all the available evidence
General population screening for ovarian and tubal cancer 
with either approach used in UKCTOCS cannot currently be 
recommended. We need a screening strategy that can detect 
ovarian and tubal cancer in asymptomatic women even 
earlier in its course and in a larger proportion of women than 
the tests used in the trial. Meanwhile, our results emphasise 
the importance of having ovarian and tubal cancer mortality 
as the primary outcome in screening trials.
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screening in a 1:1:2 ratio. The trial management system 
allocated a set of 32 random numbers to each regional 
centre, of which eight were allocated to MMS, eight to 
USS, and the remaining 16 to no screening. We randomly 
allocated each successive volunteer within the regional 
centre to one of the numbers and subsequently randomly 
allocated them into a group. Investigators and partici-
pants were aware of group allocation but members of the 
outcomes committee were masked to randomisation 
group.
Procedures
Annual screening in the MMS group used serum CA125 
measurements, with the pattern over time interpreted 
using the risk of ovarian cancer (ROCA) calculation,13 
which identifies significant rises in CA125 concentration 
above baseline. On the basis of risk, women were 
triaged to normal (annual screening), intermediate 
(repeat CA125 ROCA test in 3 months), and elevated 
(repeat CA125 ROCA test and transvaginal USS as a 
second-line test in 6 weeks) risk. Annual screening in 
the USS group used TVS as the primary test, which was 
classified as normal (annual screening), unsatisfactory 
(repeat in 3 months), or abnormal (scan with a senior 
ultrasonographer within 6 weeks). In both groups, 
women with persistent abnormalities were assessed by 
a trial clinician and referred to the NHS where they 
underwent further investigation or surgery. We deemed 
women who had surgery or a biopsy for suspected 
ovarian cancer after clinical assessment as screen 
positive.
Women were linked using their NHS number to 
national cancer and death registration data and Hospital 
Episode Statistics records (appendix p 4). An additional 
questionnaire was sent in June, 2020, to a subset of 
participants who had either exited the national registries 
or for whom it was not possible from Hospital Episode 
Statistics data to ascertain if both ovaries had been 
removed.
Throughout the trial, we interrogated the available 
sources to identify women diagnosed with any of 
19 International Classification of Diseases (ICD)-10 codes 
for possible ovarian or tubal cancer and retrieved copies 
of medical notes.12,14 The only exception was women 
with malignant neoplasm without specification of site 
(ICD-10 C80), who also had another non-ovarian, tubal, 
or peritoneal cancer registration. Medical notes, with 
any mention of randomisation group redacted, were 
reviewed by the outcomes review committee consisting 
of gynaecological pathologists and onco logists (NS, 
RM, RW, RA, LC, AS, and KW). The outcomes review 
committee assigned cancer site (ie, whether ovarian, 
tubal, or other site using a previously audited prespecified 
algorithm),14 Federation of Gynecology and Obstetrics 
(FIGO) 2014 stage, grade, morphology, ovarian cancer 
type, and cause of death. We defined ovarian and tubal 
cancer using the WHO 2014 classi fication15,16 and death 
due to ovarian and tubal cancer based on disease 
progression (new or increases in size of previously 
documented lesions on imaging, clinical worsening, or 
rising biomarker concentrations). In the WHO 2014 
classification, the definition for primary peritoneal 
cancers was revised. The outcomes review committee 
chair (NS) reviewed all 41 cancers previously classified as 
primary peritoneal as per WHO 2003 classification.9 The 
outcomes review committee re-staged all ovarian and 
tubal cancers using FIGO 2014 criteria (previously staged 
using FIGO 2003) diagnosed in 2001–14.
Outcomes
The primary outcome was death due to ovarian 
(ICD-10 C56) or tubal (ICD-10 C57·0) cancer. Ovarian 
cancer includes primary non-epithelial ovarian cancer, 
border line epithelial ovarian cancer, and invasive 
epithelial ovarian cancer. As stated above, ovarian cancer 
was defined using the revised WHO 2014 definition.15,16 
The site assignment is in contrast to the previous 
mortality analysis (censorship Dec 31, 2014), which used 
the WHO 2003 definition.17 The majority (40 of 41) of 
previously classified primary peritoneal cancers using 
WHO 2003 criteria were reclassified as ovarian or tubal 
cancers. Secondary outcomes were ovarian and tubal 
cancer incidence and stage. For all outcomes, subgroup 
analysis was undertaken for invasive epithelial ovarian 
and tubal cancer. All outcome data were kept confidential 
until unmasking. Case fatality rate by stage was a post-
hoc outcome.
Statistical analysis
At previous analysis (censorship Dec 31, 2014), there 
were 358 ovarian and tubal cancer deaths in the no 
screening group.9 Compared with the no screening 
group, the mean estimated relative mortality reduction 
in deaths was 11% (Cox model p=0·24) in the MMS 
group and 9% (Cox model p=0·32) in the USS group. 
Any mortality reduction was only apparent about 7 years 
after randomisation. 162 (45%) of 358 of the deaths in 
the no screening group during 2001–14 occurred before 
7 years. In 2015, for the no screening versus MMS or 
USS comparisons, we estimated that an additional 
233 no screening group events would give 80% power at 
a two-sided 5% significance level for a difference in 
relative mortality of 25% during long-term (2015–20) 
follow-up, conditional on the observed mortality 
reduction of 11%. This estimate translated to a target 
sample size of 591 overall events in the no screening 
group: all 233 new and 73% (431 of 591) of total no 
screening group events would occur beyond 7 years. 
No formal adjustment was made to the test for having 
previously analysed the data in 2015 or making 
two screen group comparisons. Instead, we decided to 
openly describe the multiplicity issues and acknowledge 
the unadjusted p values. As the number of events were 
less than anticipated on the planned censorship date 
See Online for appendix
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of Dec 31, 2018, follow-up was extended with a new 
censorship date of June 30, 2020.
Descriptive statistics regarding ovarian cancer death 
and incidence were created including tabulations of 
histology, stage, and screen type by group. The primary 
mortality analysis was changed from the 2016 report, in 
which we used a Cox version of the log-rank test,9 
which is most powerful under proportional hazards. For 
the current analysis, we extensively discussed the best 
approach within trial management and trial steering 
committees, and consulted 12 independent international 
statistical, trial, and screening experts. The details and 
rationale underpinning this important change are 
reported separately.18 In short, given the accumulating 
external evidence of delayed mortality effects in 
screening trials, most experts supported the change in 
primary analysis to a test that was sensitive to delayed 
effects. We chose the versatile test that was agnostic to 
the specific form of the screening effect. The versatile 
test, described in 2016,18 is a combination test of 
three log-rank test statistics (Z1, Z2, Z3), covering early, 
constant, and late effects respectively (appendix p 3).
All analyses were by intention to screen. The primary 
mortality analysis was an MMS versus no screening and 
Figure 1: Trial profile
MMS=multimodal screening. USS=ultrasound screening. *Events occurred before recruitment, but were discovered after randomisation.
101 359 assigned no screening 
101 314 included in primary analysis 





3 exited registry before 
randomisation
5038 incomplete follow-up
5038 declined or exited registry 
before June 30, 2020
50 639 assigned USS 
1 243 282 women assessed for eligibility 
205 090 enrolled
202 638 randomised
50 623 included in primary analysis
48 022 complete follow-up 









2 ovarian cancer diagnosed 
before randomisation
2 exited registry before 
randomisation
2601 incomplete follow-up
2601 declined or exited registry 
before June 30, 2020
1 038 192 ineligible
78 225 self-reported as not meeting inclusion criteria
172 149 declined to participate
777 626 did not respond
10 192 not recruited as target reached
2452 excluded
1402 did not meet inclusion criteria
1050 declined to participate
50 640 assigned MMS
50 625 included in primary analysis
48 110 complete follow-up









2 ovarian cancer diagnosed 
before randomisation
2 exited registry before 
randomisation
2515 incomplete follow-up
2515 declined or exited registry 
before June 30, 2020
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USS versus no screening analysis of the primary outcome 
using the versatile test,19 with a Royston-Parmar model to 
estimate survival differences. We defined survival time 
from date of randomisation (t0=0) to date of death due to 
ovarian or tubal cancer or censorship, or sooner if the 
volunteer died of another cause or was lost to follow-up. 
No allowances were made for screening non-compliance 
(study groups) or contamination (no screening group). 
We describe potential time-dependent features of the 
screening effect by estimating the hazard ratio (HR) 
and the absolute survival difference at the prespecified 
timepoints of 5, 10, 15, and 18 years (maximal follow-up 
was 19·3 years) using a flexible parametric Royston-
Parmar model (appendix p 3).
We undertook two secondary analyses of the primary 
outcome. We fitted a proportional hazards Cox model to 
the primary outcome data. To allow for a formal analysis 
of the late effects of ovarian cancer, not subject to issues 
of data re-use and multiple testing, we also fitted a 
Cox model to the new data acquired since Jan 1, 2015. 
Both the methods and results of sensitivity analyses are 
detailed in the appendix (pp 8–9). Survival from diag-
nosis in women with ovarian and tubal cancer in the no 
screening group was also compared to national age and 
period adjusted survival rates at 1, 5, and 10 years. We 
undertook a subgroup analysis using the versatile test 
of invasive epithelial ovarian and tubal cancer death, in 
which other ovarian cancers were censored at death.
For the secondary outcome, cumulative incidence of 
ovarian and tubal cancer were presented graphically 
using standard Kaplan-Meier methods, based on time 
from randomisation to diagnosis. Death from other 
causes and bilateral salpingo-oophorectomy were 
censoring events. Administrative censorship was the 
same as for the mortality analysis (June 30, 2020). 
Ovarian and tubal cancer incidence rates were explored 
parametrically using a Royston-Parmar model that 
specifically allowed exploration of the underlying hazard 
functions for cancer incidence. For the secondary 
outcome of ovarian and tubal cancer incidence by stage, 
and the subgroup analysis of invasive epithelial ovarian 
and tubal cancers, we used incidence rate ratios with 
95% CIs to compare no screening versus MMS and 
USS groups separately. We also calculated stage-specific 
ovarian and tubal cancer case fatality rates.
We used Stata, version 16 (versatile test verswlr 
function) for all statistical analyses. Results were 
independently verified by a different statistician using R, 
version 4.0.2 (versatile test logrank.maxtest of nph 
package). This trial is registered with ISRCTN, 22488978, 
and ClinicalTrials.gov, NCT00058032.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Between April 17, 2001, and Sept 29, 2005, we invited 
1 243 282 women to participate and randomly assigned 
Total Screen 
positives
Cancers not detected by screening
Screen negatives 
≤1 year from last test 
of screening episode
Screen negatives 




Diagnosed >1 year 
after end of 
screening*
Multimodal screening (50 625 women, 789 129 women-years)
Ovarian and tubal cancer 522 (100%) 212 (41%) 41 (8%) 41 (8%) 3 (1%) 225 (43%)
Non-epithelial ovarian cancer 16 (100%) 7 (44%) 2 (13%) 2 (13%) 0 5 (31%)
Borderline epithelial ovarian cancer 54 (100%) 24 (44%) 10 (19%) 5 (9%) 0 15 (28%)
Invasive epithelial ovarian and tubal 
cancer
452 (100%) 181 (40%) 29 (6%) 34 (8%) 3 (1%) 205 (45%)
Ultrasound screening (50 623 women, 790 231 women-years)
Ovarian and tubal cancer 517 (100%) 164 (32%) 63 (12%) 50 (10%) 19 (4%) 221 (43%)
Non-epithelial ovarian cancer 13 (100%) 11 (85%) 0 1 (8%) 0 1 (8%)
Borderline epithelial ovarian cancer 59 (100%) 48 (81%) 2 (3%) 1 (2%) 3 (5%) 5 (8%)
Invasive epithelial ovarian and tubal 
cancer
445 (100%) 105 (24%) 61 (14%) 48 (11%) 16 (4%) 215 (48%)
No screening (101 314 women, 1 577 517 women-years)
Ovarian and tubal cancer 1016† (100%) ·· ·· 514 (51%) ·· 499 (49%)
Non-epithelial ovarian cancer 17 (100%) ·· ·· 7 (41%) ·· 10 (59%)
Borderline epithelial ovarian cancer 91 (100%) ·· ·· 50 (55%) ·· 41 (45%)
Invasive epithelial ovarian and tubal 
cancer
905 (100%) ·· ·· 457 (50%) ·· 448 (50%)
Data are n (%). *Screening end Dec 31, 2011. †Includes one case in which histology was not available and two cases of neoplasm of uncertain or unknown behaviour. 
Table 1: Ovarian and tubal cancers grouped by primary site and screening status
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202 638 (16·3% of 1 243 282; figure 1).10 We followed-up 
participants until June 30, 2020. The final cohort 
eligible for analysis consisted of 202 562 (>99·9%) of 
202 638 women: 50 625 (>99·9%) in the MMS group, 
50 623 (>99·9%) in the USS group, and 101 314 (>99·9%) 
in the no screening group. We excluded 76 (<0·1%) 
women (15 [<0·1%] in the MMS group; 16 [<0·1%] in the 
USS group; and 45 [<0·1%] in the no screening group; 
figure 1) as they had bilateral salpingo-oophorectomy, 
ovarian cancer before joining the trial, or had exited the 
registry before randomisation. As previously reported, 
baseline characteristics were balanced between the 
groups.9 Screening ended on Dec 31, 2011. We undertook 
673 345 annual screens: 345 570 in the MMS group and 
327 775 in the USS group. Compliance with screening 
was high (81% in the MMS group and 78% in the 
USS group) with women undergoing a median of 
eight annual screens.9
After the end of annual screening on Dec 31, 2011, all 
women were followed up until the censorship date of 
June 30, 2020. Complete follow-up until censorship 
or death was possible in 192 478 (95·0%) women 
(48 110 [95·0%] in the MMS group; 48 022 [94·9%] in the 
USS group; and 96 276 [95·0%] in the no screening 
group) resulting in 3·16 million women-years. Median 
follow-up was 16·3 years (IQR 15·1–17·3) for all groups.
Figure 2: Kaplan-Meier cumulative incidence per 100 000 women for all ovarian and tubal cancers (A) and for invasive epithelial ovarian and tubal cancers (B)
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MMS vs no screening HR 1·04 (95% CI 0·93–1·15); p=0·51
USS vs no screening HR 1·04 (95% CI 0·94–1·16); p=0·43
MMS vs no screening HR 1·01 (95% CI 0·90–1·13); p=0·92
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We identified 4482 women with the 19 prespecified 
ICD-10 codes for possible ovarian and tubal cancer 
who were reviewed by the outcomes review committee 
(appendix p 5). Of them, 2055 (45·9%) were confirmed to 
have ovarian or tubal cancer (table 1). The incidence 
of ovarian and tubal cancer per 100 000 women-years 
was 67·7 (95% CI 61·9–73·5; 522 cancers; 770 967 women-
years) in the MMS group, 68·2 (62·4–74·1; 517 cancers; 
755 677 women-years) in the USS group, and 65·4 
(61·4–69·4; 1016 cancers; 1 552 703 women-years) in the 
no screening group (appendix p 11). Figure 2A provides 
Kaplan-Meier cumulative cancer rates for all women and 
figure 2B provides Kaplan-Meier cumulative cancer rates 
for invasive epithelial ovarian and tubal cancers. Both 
plots show a greater number of cancer diagnoses in 
the screening groups during the first screening year, 
reflecting the lead time to diagnosis achieved by screening. 
The difference was largely maintained throughout the 
screening phase before apparent catch-up by the no 
screening group during the extended period of follow-up 
after the end of screening. However, the pattern of catch-up 
in the USS group was less pronounced, and this 
observation is elucidated by the Royston-Parmar model 
hazard functions (appendix pp 19–20), in which the 
rate of cancer incidence drops below the no screening 
group between years 4–14 approximately, before rising 
back above the no screening group rate.
Overall, 1805 (87·8%) of 2055 women (452 [0·9%] in 
the MMS group; 445 [0·9%] in the USS group; 
905 [0·9%] in the no screening group) had invasive 
epithelial ovarian or tubal cancers. The proportion of 
the most aggressive type II cancers (79·2% in the MMS 
group; 82·2% in the USS group; and 76·4% in the no 
screening group) was similar across the groups 
(appendix p 6). At 9·5 years after the end of screening, 
compared with the no screening group, there was a 
47·2% (95% CI 19·7 to 81·1) higher incidence of stage I 
disease and a 24·5% (–41·8 to –2·0) lower incidence of 
stage IV disease in the MMS group (table 2). Overall, 
there was a 39·2% (95% CI 16·1 to 66·9) higher 
incidence of stage I or II disease and 10·2% (–21·3 to 2·4) 
lower incidence of stage III or IV disease in the MMS 
FIGO 2014 stage Total
I II III IV Unable to stage
Ovarian and tubal cancers (WHO 2014 classification)*
No screening
Cases 212 (20·9%) 73 (7·2%) 510 (50·2%) 208 (20·5%) 13 (1·3%) 1016
Deaths 20 (9·4%) 24 (32·9%) 391 (76·7%) 174 (83·7%) 10 (76·9%) 609 (59·9%)
MMS
Cases 155 (29·7%) 42 (8·0%) 242 (46·4%) 78 (14·9%) 5 (1·0%) 522
Deaths 23 (14·8%) 16 (38·1%) 190 (78·5%) 62 (79·5%) 4 (80·0%) 291 (55·7%)
USS
Cases 121 (23·4%) 36 (7·0%) 253 (48·9%) 105 (20·3%) 2 (0·4%) 517
Deaths 8 (6·6%) 6 (16·7%) 188 (74·3%) 88 (83·8%) 2 (100·0%) 290 (56·1%)
Between group differences in cases compared with no screening at 9·5 years after end of screening†
MMS 47·2% (19·7 to 81·1) 15·9% (–20·7 to 69·4) –4·4% (–18·0 to 11·4) –24·5% (–41·8 to –2·0) ·· ··
USS 17·0% (–6·4 to 46·2) 1·1% (–32·2 to 50·6) 1·7% (–12·6 to 18·2) 3·4% (–18·2 to 30·8) ·· ··
Invasive epithelial ovarian and tubal cancers (WHO 2014 classification)*
No screening
Cases 116 (12·8%) 69 (7·6%) 501 (55·3%) 208 (23·0%) 12 (1·3%) 906
Deaths 18 (15·5%) 24 (34·8%) 391 (78·0%) 174 (83·7%) 10 (83·3%) 617 (68·1%)
MMS
Cases 91 (20·1%) 41 (9·1%) 237 (52·4%) 78 (17·3%) 5 (1·1%) 452
Deaths 22 (24·2%) 16 (39·0%) 190 (80·2%) 62 (79·5%) 4 (80·0%) 294 (65·0%)
USS
Cases 55 (12·4%) 35 (7·9%) 249 (56·0%) 104 (23·4%) 2 (0·4%) 445
Deaths 7 (12·7%) 6 (17·1%) 186 (74·7%) 87 (83·7%) 2 (100·0%) 288 (64·7%)
Between group differences in cases compared with no screening at 9·5 years after end of screening†
MMS 52·2% (16·8 to 98·4) 15·8% (–19·4 to 66·4) –4·8% (–18·3 to 10·9) –23·7% (–40·7 to –1·7) ·· ··
USS –8·0% (–32·7 to 25·7) –5·2% (–35·8 to 39·9) 0·5% (–13·6 to 16·8) –0·8% (–21·3 to 25·1) ·· ··
Data for cases are n (%); data for deaths are n (case fatality rate for stage); data for between group differences in cases are percentage (95% CI). FIGO=Federation of 
Gynecology and Obstetrics. MMS=multimodal screening. USS=ultrasound screening. *Includes cases previously designated as primary peritoneal cancer as per WHO 2003 
classification. †Between group differences from a poisson model with length of analysis time as exposure variable; percentage difference taken from the incidence rate ratio, 
where percentage difference equals incidence rate ratio minus 1 multiplied by 100%. 
Table 2: Summary of incidence and case fatality rate by FIGO 2014 stage for ovarian and tubal cancer
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group compared with the no screening group. For the 
subgroup analysis of invasive epithelial ovarian and 
tubal cancers, the changes in stage distribution in the 
MMS group compared with the no screening group 
persisted. There was no evidence of a change in 
incidence in any stage in the USS group compared with 
the no screening group.
At censorship, 1206 (0·6%) women had died of ovarian 
cancer: 296 (0·6%) of 50 625 in the MMS group, 
291 (0·6%) of 50 623 in the USS group, and 619 (0·6%) 
of 101 314 in the no screening group. Ovarian and tubal 
cancer deaths and incidence by year from randomisation 
is detailed in the appendix (p 7). The versatile test 
(primary analysis) showed that there was no evidence of 
a reduction in ovarian and tubal cancer deaths in either 
the MMS (p=0·58) or USS (p=0·36) group compared 
with the no screening group (table 3). Figure 3 shows the 
Kaplan-Meier cumulative death rates, with any diver-
gence between the screen and no screen groups being 
minimal. A sensitivity analysis that only considered data 
obtained by equivalent means of electronic health records 
across all three groups also showed no evidence of a 
difference using the versatile test result for both the 
MMS (p=0·60) and USS (p=0·37) group (appendix p 9). 
This analysis and other sensitivity analyses are detailed 
in the appendix (pp 8–9). A Cox model (secondary 
analysis) estimated a HR of 0·96 (95%CI 0·83–1·10) for 
MMS versus no screening and 0·94 (0·82–1·08) for USS 
versus no screening. A Cox model fitted only to data 
from 2015 onwards (secondary analysis) estimated a 
HR of 1·05 (95%CI 0·86–1·30) for MMS versus no 
screening and 0·99 (0·80–1·22) for USS versus no 
screening.
For the secondary outcome of invasive epithelial 
ovarian and tubal cancers, there were 295 (0·6%) deaths 
in the MMS group, 287 (0·6%) in the USS group, and 
619 (0·6%) in the no screening group (table 3). The 
cumulative death rates similarly showed no evidence of 
an effect of screening (appendix p 11). The versatile test 
for mortality reduction showed no evidence of dif-
ference in both the MMS group (p=0·60) and the USS 
group (p=0·33). The appendix shows the Royston-
Parmar model fit to the non-parametric Kaplan-Meier 
curves (pp 12–13) and the associated hazard functions 
for each group (pp 14–15). All hazard functions were 
consistently increasing with only small differences 
between the screening and no screening groups. At 
18 years after randomisation, the Royston-Parmar model 
estimates of survival differences per 100 000 women 
were 36·7 (95% CI –65·3 to 138·8) for MMS compared 
with no screening and 52·9 (–48·2 to 153·9) for USS 
compared with no screening (figure 3, appendix p 10).
Compared with no screening, in the MMS group, we 
observed a higher ovarian and tubal cancer case fatality 
rate in patients with stage I disease (20 [9·4%] of 212 in 
the no screening group vs 23 [14·8%] of 155 in the 
MMS group) and a lower rate with stage IV disease 
(174 [83·7%] of 208 in the no screening group vs 
62 [79·5%] of 78 in the MMS group), which persisted 
on subgroup analysis of invasive epithelial ovarian 
cancer. In the USS group, the stage-specific case fatality 
rates appear to be similar to the no screening group, 
except for stage II, but numbers in this group are small 
(table 2).
Survival from diagnosis in women with ovarian and 
tubal cancer in the no screening group was better in 
comparison to national age and period adjusted survival 
rates (1 year 77% vs 68%; 5 year 40% vs 37%; appendix 
p 18).
Discussion
Our results from the largest ovarian cancer screening 
trial to date show that on long-term follow-up (median 
16·3 years after randomisation), neither MMS or USS, as 
used in UKCTOCS, significantly reduced deaths from 
ovarian and tubal cancer. There was a 47·2% higher 
incidence of stage I cancer and 24·5% lower incidence of 
stage IV cancer, resulting in an overall 39·2% higher 
incidence of stage I or II cancer and 10·2% lower 
incidence of stage III or IV cancer in the MMS group 
than in the no screening group. General population 
screening for ovarian and tubal cancer with either of the 
screening strategies cannot be recommended based on 
evidence to date. The changes in stage distribution in the 
MMS group did not translate into mortality reduction, 
emphasising the importance of having disease-specific 
mortality as the primary outcome in ovarian cancer 
screening trials.
All women were treated within the NHS where, 
since 2004, patients are managed within a designated 
Number of 
women (n)
Deaths (n) Maximum χ² or mortality 
reduction (hazard ratio) 
p value
Primary analysis* (ovarian and tubal cancer deaths)
MMS 50 625 296 0·41 0·58
USS 50 622 291 1·23 0·36
No screening 101 314 619 ·· ··
Subgroup outcome analysis* (invasive epithelial ovarian and tubal cancer)
MMS 50 625 295 0·41 0·60
USS 50 622 287 1·37 0·33
No screening 101 314 617 ·· ··
Secondary analysis† (all data 2001–20)
MMS 50 625 296 0·96 (0·83 to 1·10; 0·068) 0·52
USS 50 622 291 0·94 (0·82 to 1·08; 0·067) 0·37
No screening 101 314 619 ·· ··
Secondary analysis† (only data 2015–20)
MMS 45 999 136 1·05 (0·86 to 1·30; 0·112) 0·63
USS 46 079 128 0·99 (0·80 to 1·22; 0·107) 0·91
No screening 91 808 258 ·· ··
Data are maximum χ² for primary and subgroup analyses or mortality reduction (95% CI; SE) for secondary analyses. 
MMS=multimodal screening. USS=ultrasound screening. *Versatile test. †Cox model. 
Table 3: Summary of analyses of relative reduction of ovarian and tubal cancer deaths
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cancer-specific multidisciplinary team setting and ovarian 
cancer surgery is done only in gynaecological oncology 
cancer centres by subspecialty trained and accredited 
gynaecological oncologists. Therefore, there is unlikely to 
be variability in quality of care between the randomisation 
groups. Detailed analysis of stage and histology specific 
treatment is underway and will be the subject of a future 
report.
Achieving a mortality reduction will require a screening 
strategy that can detect ovarian and tubal cancer even 
earlier and in a larger proportion of women than we were 
able to achieve. Our findings make it even more 
important that before general population screening is 
introduced, any new test is shown to reduce ovarian and 
tubal cancer deaths in a future randomised controlled 
trial. These trials take many years to complete but the 
high compliance with annual screening in UKCTOCS 
suggests that women are very motivated to join them. 
Given that such trials take considerable time, it is 
probable that population screening for ovarian cancer is 
more than a decade away.
It is difficult to extrapolate these results to ovarian 
cancer screening of women at high-risk, in which the 
strategy has involved MMS once every 3–4 months 
alongside risk-reducing surgery and resulted in a 
significant reduction in the proportion of women 
diagnosed with advanced disease.20,21 Biological dif-
ferences also exist between cancers in women with 
BRCA gene mutations and the general population, which 
result in improved treatment responses in carriers of 
BRCA mutations. Unfortunately, it is unlikely that the 
true effect of screening on mortality will ever be assessed 
in this population as a randomised controlled trial is 
challenging, and potentially very effective preventive 
measures such as risk reducing salpingectomy with 
delayed oophorectomy are being evaluated.
Our results have implications for ovarian cancer 
symptom awareness campaigns as most women who 
were screen-detected had no high-alert symptoms22 and 
were diagnosed earlier than would have been possible 
with a symptom-based approach. Our findings suggest 
that earlier diagnosis of invasive epithelial ovarian and 
tubal cancer in the symptomatic population is unlikely 
to translate into reduced mortality. However, it is 
important to note that there have been substantial 
advances in the treatment of advanced disease in the 
past 10 years since the end of screening in Dec 31, 2011. 
The advances in treatment, in combination with earlier 
diagnosis could contribute to better quality of life 
and improved outcomes. In addition, achieving a rapid 
diagnosis is of great importance to women and their 
families.
Our mortality results are similar to those reported 
for ovarian cancer screening in the Prostate Lung 
Colorectal Ovarian (PLCO) cancer screening trial, the 
only other large randomised controlled trial to report 
on the effects of ovarian cancer screening on mortality.7,8 
In the PLCO trial, no evidence was seen of a reduction 
in ovarian cancer deaths between the screen and no 
screen arms, either at median follow-up of 12·47 or 
14·78 years. However, in UKCTOCS, we found a higher 
incidence of stage I and lower incidence of stage IV 
disease in the MMS group than in the no screening 
group. The PLCO trial found no evidence of a difference 
in stage dis tribution between the screened and non-
screened groups.7,8 The use of a longitudinal CA125 
algorithm in the MMS group instead of a single CA125 
cutoff, as in the PLCO trial, might have contributed to 
this difference. We have previously shown that a 
longitudinal algorithm allows us to detect disease 
earlier and with greater sensitivity than a single CA125 
cutoff.23,24
Figure 3: Kaplan-Meier cumulative mortality for ovarian and tubal cancer per 100 000 women
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Versatile test: MMS vs no screening p=0·58; USS vs no screening p=0·36
Number of deaths avoided (absolute survival difference) per 100 000 women
at 18 years after randomisation*: MMS vs no screening 36·7 (95% CI
–65·3 to 138·8); USS vs no screening 52·9 (–48·2 to 153·9)
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Despite the 24·5% reduction in stage IV disease in 
the MMS group, the overall reduction in stage III or IV 
incidence 9·5 years after end of screening was only 10%, 
with little change in stage III incidence. Previous reports 
have highlighted the need for a large reduction in late-
stage incidence as a prerequisite for reducing cancer 
mortality. However, it should be noted that the length of 
follow-up and, therefore, the dilution effect in the screen 
groups of inclusion of cancers diagnosed clinically after 
end of screening varied in these reports. An analysis of 
breast cancer screening trials found no reduction in 
breast cancer mortality in trials that achieved less than 
10% reduction in stage III or IV disease and a mean 
reduction of 28% in trials that saw a 20% or greater 
reduction.25 In colorectal and lung cancer screening, 
much of the mortality reduction is related to reductions 
in stage IV disease, which has much higher mortality 
than earlier stages.26,27 For ovarian and tubal cancer, the 
high mortality associated with stage III and IV disease, 
combined with most women clinically detected with 
stage III disease, requires a substantial reduction in the 
incidence of both stages before a mortality reduction is 
possible.
There are previous instances in which increased 
incidence of stage I or II cancers in the screen group in 
screening trials did not translate to a mortality reduction. 
In the four early randomised controlled trials of lung 
cancer,28 compared with the control group, the screened 
groups showed significant improvements in stage 
distribution. However, much of the screen-detected early 
stage disease cases in these trials were indolent. This 
finding in the lung cancer trials was accompanied by a 
significant increase in cancer incidence in the screen 
groups, but no reduction in late-stage incidence. Both 
together suggest that overdiagnosis was the main con-
tributor to the absence of reduction in mortality.28 This 
result differs from UKCTOCS, in which no significant 
increase in cancer incidence was observed in either of 
the screen groups. In the MMS group of UKCTOCS, 
it seems probable that the cancers shifted to an earlier 
stage had an intrinsic poor prognosis, which was not 
altered by earlier detection and the available treatments 
for early stage disease. Further histo pathological and 
genetic analysis of these early stage screen-detected 
cancers could yield important infor mation about the 
biology of ovarian cancer.
The 47·2% increase in incidence of stage I and 
24·5% decrease in incidence in stage IV disease was 
accompanied by a higher stage I and lower stage IV case 
fatality rate in the MMS group. This finding persisted in 
subgroup analysis of invasive epithelial cancers. The 
findings are unlike that described previously in cancer 
screening trials.26 The result suggests that in the MMS 
group, although earlier detection of stage IV invasive 
epithelial ovarian and tubal cancers improved outcomes, 
earlier detection in stage I cancers that might have 
presented in later stages in the absence of screening, did 
not have the same effect. Stage-specific mortality and 
treatment will be the subject of further in-depth analyses, 
which will be reported in a separate publication.
The key strengths of UKCTOCS have been previously 
detailed9 and include scale; multicentre design; 
adherence to protocol through use of a bespoke web-
based trial management system with automation of key 
processes, remote data entry, and concurrent central 
monitoring; completeness of follow-up through linkage 
to national registries and administrative databases; and 
independent assignment of site and cause of death. The 
longitudinal algorithm we used since 2001 to interpret 
CA125 concentrations was innovative and forward 
thinking. The UK Government’s Accelerating Detection 
of Disease Programmme includes collection of repeat 
biological samples that will enable building of such 
algorithms. We re-staged all cases using the latest 
FIGO 2014 criteria and revised our ovarian and tubal 
cancer site assignment using WHO 2014 classification to 
reflect current understanding of disease biology. We also 
changed our primary analysis approach from a constant-
effect approach (proportional hazards Cox-model) to 
one that allows for a delayed effect (the versatile test) to 
reflect growing evidence that the mortality reduction 
in cancer-screening trials, if present, is delayed. We did 
this through a transparent process with publication of 
our methods and the expert opinions that underpinned 
our decision.18
Much has been learnt from the design, conduct, and 
analysis of UKCTOCS, which is relevant to future 
large-scale trials. In addition, a large bioresource of 
serum samples (>550 000) and linked data (UKCTOCS 
Longitudinal Women’s Cohort) has been built through 
the generosity of the participants. The resource includes 
a rare sample set of up to 11 annual blood samples from 
women in the MMS group. In ovarian cancer, it has 
allowed us to collaborate to explore new biomarkers and 
develop longitudinal algorithms.24 The data provides a 
unique opportunity to study the natural history of ovarian 
and tubal cancer. Important research is also underway on 
early detection of other cancers and risk stratification in 
cardiovascular disease using this bioresource.
A key limitation of the trial is the interval from end of 
screening in 2011 to censorship in 2020, which raises the 
possibility of dilution of the screening effect. However, 
extended follow-up after screening is the norm in 
screening trials and did not affect mortality reduction 
seen in the European Randomized Study of Screening 
for Prostate Cancer.29 Also, there was no variation in the 
ovarian cancer mortality HR at 15 years and 18 years 
from randomisation in our Royston-Parmar model 
(appendix p 10).
In addition, most screen-detected women were 
diagnosed and treated more than a decade ago, before 
many of the advances in clinical management (eg, 
widespread use of ultraradical surgery, earlier treatment 
modulation based on better prognostic indicators, and 
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targeted therapies), which could have improved out-
comes. In retrospect, second-line tests could have been 
further optimised so that time to diagnosis after an 
abnormal screen was reduced.23 Finally, clinicians could 
have been encouraged to intervene earlier when faced 
with rising biomarker concentrations and normal 
imaging.30 This theory is supported by modelling, which 
suggests that the majority of stage I, type II epithelial 
cancers are 0·4–1·3 cm in diameter and, therefore, 
difficult to reliably image.31
We began our mission to reduce deaths from ovarian 
cancer in the 1980s,5,6 started our pilot randomised 
controlled trial in the mid-1990s,32 and then undertook 
UKCTOCS over the next 20 years. The journey has 
involved more than 200 000 women who have trusted us 
and generously given their time, multiple UK funding 
agencies, numerous NHS staff both at the trial centres 
and more widely, and the support of many UK and 
international charities, and expert groups. To them, we 
are hugely grateful. While disappointing, the trial has 
provided a clear answer that our screening strategies 
coupled with treatment protocols available in 2001–11 
(the active screening phase) did not save lives. Currently, 
general population screening for ovarian and tubal 
cancer cannot be recommended. We remain optimistic 
that further research will develop more effective ways to 
detect and treat this lethal disease. Meanwhile, the 
UKCTOCS biorepository with longitudinal samples 
provides a unique opportunity to advance early detection 
biomarker research.
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